Solventum's (SOLV) Q2 Earnings Beat Estimates, ' 24 View Raised
Solventum's (SOLV) second-quarter results show resilience in MedSurg and Health Information Systems. Its shrinking margins pose concerns.
Solventum Corporation (SOLV) Q2 2024 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kevin Moran - Senior Vice President, Investor Relations Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Vik Chopra - Wells Fargo David Roman - Goldman Sachs Operator Good day. My name is Ellie, and I will be your conference operator for today.
Solventum's second-quarter profit falls 70% on higher expenses
3M spin-off Solventum's second-quarter profit fell more than 70% on Thursday, hurt by limited sales growth of its wound care and surgical sterilization products and higher expenses, as it navigates functioning as a newly independent company.
Activist Trian has a few levers to pull to build shareholder value at Solventum
Since its spinoff from 3M, Solventum has been under-covered and misunderstood by the market.
SOLV Stock Alert: Solventum Pops as Activist Investor Trian Capital Takes Stake
Solventum (NYSE: SOLV ) stock is up on Tuesday after activist investor Trian Capital took a stake in the healthcare company. According to insider sources, Trian Capital has taken a large stake in the company.
Solventum Stock Jumps as Activist Trian Discloses Stake
The move comes just months after 3M spun off the healthcare product company.
Nelson Peltz's Trian said to build stake in 3M spinoff Solventum, Bloomberg News reports
Activist investor Nelson Peltz's Trian Fund Management has built a stake in 3M's healthcare spinoff Solventum , Bloomberg News reported on Monday, citing people with knowledge of the matter, sending shares of the company up 3.4% after the bell.
